Chicken Pox - epidemiology, prevention, control Also provide image for this
chickenpox varicella rash skin lesions
A comparative side-by-side clinical photograph illustrating the progression of primary varicella (chickenpox) rash in a rhesus macaque model. The left panel shows the baseline pre-inoculation state, displaying clear skin on the neck, torso, and abdomen with normal anatomical markings and identifying tattoos. The right panel, captured at 9 days post-inoculation (dpi), demonstrates a severe, generalized acute skin rash. The morphology of the lesions includes a dense distribution of small, erythematous (reddish/pinkish) macules and papules. The rash is widespread, involving the neck, shoulders, chest, and ventral abdomen. This comparison serves to highlight the clinical manifestation of Simian Varicella Virus (SVV), which mirrors the presentation of Varicella-Zoster Virus (VZV) in humans, focusing on the density, distribution, and characteristic appearance of primary varicella lesions.
Clinical photography of skin lesions depicting a varicella (chickenpox)–like vesicular exanthem concentrated on the trunk with scattered papules and crusted lesions. The image shows numerous small erythematous papules with central vesiculation and crust formation on a backdrop of unremarkable skin. In classic varicella, lesions appear in crops, evolving from macules to vesicles (dew drops on a rose petal) and eventually crusting, often involving the trunk more than the face, and accompanied by pruritus, fever, and malaise. The depicted lesion is in a later crusted stage, while adjacent lesions are in various stages, reflecting the dynamic evolution of the eruption. Relevant imaging: not radiologic; this is dermatologic clinical photography. Diagnostic relevance: a hallmark varicella rash that aids rapid clinical diagnosis in outpatient or inpatient settings, allowing differential with disseminated herpes simplex, pityriasis rosea, or pityriasis versicolor; contagious until crusting. Clinically, management includes supportive care, antipyretics, antihistamines for itch, and antiviral therapy in high-risk patients; infection control measures to prevent transmission. Potential educational uses include dermatology training, telemedicine triage, clinical case discussions, and AI-based image retrieval for vesicular exanthems.
Clinical photography of active varicella (chickenpox) rash on the frontal scalp and forehead of a pediatric patient. Modality: digital color photograph taken under ambient lighting; standard clinical technique without dermoscopy or fluorescence. The image shows numerous small vesicles on an erythematous, slightly raised base distributed across the forehead and extending toward the temple. Lesions are in multiple evolutionary stages, with some vesicles capturing clear serous content, others showing crusted surfaces, and crusts around the margins. The pattern is characteristic of varicella: centripetal distribution with trunk and face involvement, crops of lesions appearing sequentially, and a tendency for vesicles to be more numerous on exposed skin areas. The epidermis and superficial dermis contain superficial fluid-filled vesicles, each about 2-4 mm in diameter, some conforming to the classic dew drop on a rose petal description. Facial involvement may accompany fever and malaise in pediatric patients. Although lesions may be pruritic, Nikolsky sign is typically absent; scarring is uncommon in children. Diagnosis is clinical, supported by history of varicella exposure or vaccination status; differential includes disseminated herpes zoster, pityriasis rosea, and vesicular dermatitis. Recognizing multistage lesions in a contagious exanthem is clinically significant for isolation, supportive therapy, and public health reporting as Varicella-zoster virus infection.
Clinical photograph of a pediatric patient's face and upper neck demonstrating a pleomorphic skin eruption characteristic of varicella-zoster virus (chickenpox) infection. The image shows multiple small lesions in varying stages of evolution, including erythematous and reddish-brown maculopapules, crusting lesions with scab formation, and small residual hypopigmented macules indicating sites of previous inflammation. The lesions are distributed across the cheek, nose, and neck. This variety of lesion stages (the 'starry sky' appearance) is a hallmark diagnostic feature of varicella, representing a synchronous evolution of the rash over several days. The educational focus is on identifying clinical dermatology signs and understanding the progression of viral exanthems in pediatric medicine.
varicella chickenpox epidemiology prevention
Chickenpox (Varicella) - Epidemiology, Prevention & Control
Clinical Overview
Images
1. EPIDEMIOLOGY
Global Disease Burden
- Worldwide distribution; occurs in both epidemic and endemic forms
- Annual global burden: 4.2 million severe complications leading to hospitalization and 4,200 deaths
- Pre-vaccine era case fatality rate in high-income countries: ~3 per 100,000 cases
- India (2018): 66,963 cases reported, 50 deaths; CFR ~0.074%; Kerala had highest cases (34,785); West Bengal had most deaths (31)
Epidemiological Determinants
A. Agent Factors
| Factor | Details |
|---|---|
| Agent | VZV (Human herpesvirus 3); DNA virus |
| Source of infection | Case of chickenpox (primary); rarely, a herpes zoster patient |
| Virus location | Oropharyngeal secretions, vesicular fluid, skin/mucosal lesions |
| Scabs | NOT infective |
| Period of communicability | 1-2 days before rash appears, up to 4-5 days after rash onset |
| Latency | Establishes latent infection in cranial nerve ganglia and spinal dorsal root ganglia; reactivates as zoster in 10-30% of persons |
B. Host Factors
- Age: Primarily affects children under 10 years; adults can have severe disease
- Immunity: One attack gives durable (lifelong) immunity; second attacks are rare. Maternal IgG antibodies protect infants in the first few months of life
- Pregnancy: Infection in first 20 weeks of gestation causes congenital varicella syndrome in 0.4-2.0% of foetuses; affected infants have higher risk of developing herpes zoster in early life
- High-risk groups: Infants, pregnant women, immunocompromised patients (including HIV), adults, and those on immunosuppressive therapy
C. Environmental Factors
- Seasonal: Peak incidence in winter and spring (temperate); coolest, driest months in tropics
- Epidemic cycle: Periodic large outbreaks with an inter-epidemic cycle of 2-5 years
- Virus survival: VZV is heat-labile; survives only a few hours outside the host, occasionally 1-2 days; readily inactivated by lipid solvents, detergents, and proteases
D. Transmission
- Droplet infection and droplet nuclei (airborne spread) - primary route
- Direct contact with skin lesions
- Indirect contact via freshly soiled articles
- Highly contagious - Secondary Attack Rate (SAR): ~85% (range 61-100%) in susceptible household contacts
- Herpes zoster is ~20% as infectious as chickenpox; contact with zoster rash causes varicella (not zoster) in susceptibles
Incubation Period
- 14-16 days (range: 10-21 days, occasionally up to 23 days)
2. CLINICAL FEATURES (Summary)
| Feature | Description |
|---|---|
| Distribution | Centripetal - starts on trunk (abundant), then face, arms, legs; mucous membranes affected; palms/soles usually spared |
| Morphology | Macule → papule → vesicle ("dew drop on a rose petal") → crust; unilocular, superficial |
| Pleomorphism | All stages present simultaneously - hallmark feature, due to successive crops appearing over 4-5 days |
| Evolution | Very rapid; scabbing begins 4-7 days after rash |
| Fever | Rises with each fresh crop of rash |
3. PREVENTION
A. Active Immunization - Varicella Vaccine
- Vaccine type: Live attenuated varicella vaccine (Oka strain)
- Schedule:
- Children (12 months-12 years): 2 doses - first dose at 12-15 months, second dose at 4-6 years
- Adolescents/Adults (susceptible): 2 doses, 4-8 weeks apart
- Efficacy: ~85% against any varicella; >95% against severe disease
- Contraindications: Pregnancy, immunocompromised states (CD4 <200 cells/mm³ in HIV), recent immunoglobulin or blood products
- In HIV-positive patients with CD4 ≥200 cells/μL: two-dose VAR series 3 months apart is recommended
B. Passive Immunization - Varicella-Zoster Immune Globulin (VZIG)
- Administered to high-risk susceptible contacts within 96 hours of exposure
- Indications: susceptible pregnant women, immunocompromised individuals, neonates born to mothers with varicella
- Does not prevent infection but modifies severity
C. Chemoprophylaxis
- Acyclovir: Post-exposure prophylaxis in susceptible high-risk individuals when VZIG is unavailable
- Antiviral treatment: Acyclovir/valacyclovir for high-risk groups (adults, immunocompromised, pregnant) within 24-48 hours of rash onset
4. CONTROL MEASURES
A. Case Management
| Measure | Details |
|---|---|
| Isolation | Isolate the case from the onset of fever until ALL lesions have crusted (at least 5 days after rash onset) |
| Treatment | Symptomatic in healthy children; antiviral therapy (acyclovir) for high-risk cases |
| Notification | Notifiable disease in many countries/states |
B. Contact Management
- Identify susceptible contacts (no prior infection, no vaccination)
- Administer VZIG to high-risk susceptibles within 96 hours of exposure
- Vaccinate susceptible contacts (if not contraindicated) - post-exposure vaccination within 3-5 days can prevent or attenuate disease
- Exclude susceptible contacts from school/work for 21 days from last exposure (or 8-21 days if VZIG given)
C. Environmental Measures
- Adequate ventilation of rooms (virus spreads via airborne route)
- Terminal disinfection of contaminated articles (VZV susceptible to common disinfectants)
- Healthcare settings: airborne + contact precautions; negative pressure rooms for hospitalized cases
D. Outbreak Control
- Rapid identification and vaccination of susceptible individuals
- Exclude cases until all lesions are crusted
- Vaccination coverage of >90% in school-age children is the key to epidemic prevention
Summary Table
| Parameter | Details |
|---|---|
| Causative agent | VZV (Human herpesvirus 3) |
| Reservoir | Humans only |
| Transmission | Airborne (droplets/nuclei), contact |
| Incubation period | 10-21 days (usually 14-16 days) |
| Communicability | 1-2 days before to 4-5 days after rash |
| SAR | ~85% in household contacts |
| Immunity | Lifelong after natural infection |
| Vaccine | Live attenuated (Oka strain), 2-dose schedule |
| Isolation | Until all lesions crusted |
- Park's Textbook of Preventive and Social Medicine, pp. 163-165
- Goldman-Cecil Medicine, International Edition
- Recent systematic review: Healthcare resource use and costs of varicella (Williame et al., 2023)
- Varicella vaccine in pediatric transplant recipients - meta-analysis confirming vaccine safety and immunogenicity (Piché-Renaud et al., 2023)
SAQ 1. Measles Vaccination (Pg. 161) LAQ 1. Measles - epidemiology, control, prevention
measles rash Koplik spots maculopapular exanthem
A series of clinical photographs documenting the exanthem and enanthem of measles (rubeola) in an adult male. The oral cavity image demonstrates pathognomonic Koplik spots: tiny, bluish-white or whitish-gray macules resembling grains of sand on an erythematous base, located on the buccal mucosa. The remaining images show a generalized, blanching, erythematous maculopapular rash. This exanthem exhibits a cephalocaudal progression, appearing as numerous discrete macules and papules that have coalesced into larger patches on the back, abdomen, and extremities, including the palms and feet. The presentation illustrates the classic clinical manifestations of a primary measles infection, highlighting the diagnostic importance of the enanthem during the prodromal phase and the characteristic distribution of the subsequent skin eruption for emergency and infectious disease medicine.
Close-up clinical photograph of the oral cavity focusing on the buccal mucosa reveals characteristic small bluish-white Koplik spots embedded in erythematous mucosa. The image corresponds to early measles (rubeola) infection on illness day 1, typically preceding the maculopapular rash. Koplik spots are pathognomonic for measles, reflecting cytopathic changes in mucosal epithelial cells with inflammatory exudate and adjacent hyperemia. In this view, the lips are gently everted to expose the inner cheek, with moist mucosa and subtle surrounding erythema near the molar region. These lesions may be transient and diminish as the exanthem develops over the next 1–3 days. The photograph supports the clinical diagnosis of measles and aids differentiation from other viral exanthems where such mucosal lesions are absent or non-specific. Clinically, identification of Koplik spots prompts immediate infection control measures and confirmatory testing (measles IgM serology or RT-PCR). For educational and research use, the image highlights oral cavity involvement, buccal mucosa localization, and the temporal relationship to fever and onset of rash. Differential considerations include rubella, enteroviral infections, and aphthous lesions, but Koplik morphology and distribution are highly characteristic of measles when present. This image serves as a teaching reference for clinicians and trainees. Facilitates rapid clinical decision-making.
This clinical photograph shows the intraoral cavity and shoulder of an adult male, highlighting pathognomonic signs of a viral exanthem. The primary focus is the buccal mucosa, which is retracted to reveal Koplik's spots: multiple small, 1–2 mm, irregular, bluish-white or gray-white grain-like elevations on an erythematous base. These spots are located opposite the mandibular molars. In the background, the patient's shoulder and chest display a faint, widespread, red maculopapular rash. The image demonstrates key diagnostic features of the prodromal phase of measles (rubeola), where intraoral lesions precede the full systemic rash. This visual is suitable for medical education regarding infectious diseases, dermatology, and clinical diagnosis of childhood and adult exanthems.
measles epidemiology vaccination prevention
SAQ: Measles Vaccination (Park's Textbook, p. 161/pg. 168-170)
Measles Vaccination
Vaccine Type
- Monovalent (measles only)
- MR (Measles-Rubella)
- MMR (Measles-Mumps-Rubella)
- MMRV (Measles-Mumps-Rubella-Varicella)
Vaccine Properties
- Freeze-dried (lyophilized) product; reconstituted with sterile diluent before use
- Each dose = 0.5 ml containing ≥1000 viral infective units
- Contains sorbitol and hydrolysed gelatin as stabilizers; small amount of neomycin; no thiomersal
- Heat-labile: loses ~50% potency after 1 hour at 20°C; almost all potency after 1 hour at 37°C
- Sensitive to sunlight - stored in coloured glass vials
- Storage: 2-8°C (refrigerated); diluent must NOT be frozen but cooled before reconstitution
- After reconstitution: must be used within 4 hours, stored in dark at 2-8°C
Recommended Schedule (WHO)
| Setting | MCV1 | MCV2 |
|---|---|---|
| High-transmission / high-risk countries | 9 months | 15-18 months |
| Low-transmission / near-elimination countries | 12 months | At school entry (4-6 years) |
| Minimum interval between MCV1 and MCV2 | - | 4 weeks |
- MCV0: Supplementary dose given from 6 months of age in special situations (outbreaks, high-endemic areas, displaced populations, HIV-exposed infants, travellers to outbreak areas). Does not replace MCV1 and MCV2.
Immunity
- Immunity develops 11-12 days after vaccination
- Duration: probably lifelong
- One dose at 11-12 months: ~95% protection
- Two doses: ~98% protection
- Infants vaccinated at 9 months: seroconversion ~90%
Post-Exposure Prophylaxis
- Susceptible contacts >9-12 months: vaccine given within 3 days of exposure can protect (vaccine incubation ~7 days vs. natural measles incubation ~10 days)
Contraindications
- Severe immunosuppression (HIV with severe immunosuppression, congenital immunodeficiency, leukaemia, lymphoma, high-dose corticosteroids)
- MMRV: not approved for HIV-infected persons
- Moderate/severe acute illness: defer until recovery
- Receipt of antibody-containing blood products: delay by 3-11 months depending on product
Adverse Effects
- Toxic Shock Syndrome (TSS): occurs when vaccine is contaminated or same vial used >4 hours; presents as watery diarrhoea, vomiting, high fever within hours; cluster of cases; high CFR; totally preventable by good immunization practices
Passive Immunization (Immunoglobulin)
- Dose: 0.25 ml/kg IM, within 3-4 days of exposure
- Modifies or prevents disease
- Live vaccine should be given 8-12 weeks later
LAQ: Measles - Epidemiology, Control & Prevention
Koplik Spots (Pathognomonic Enanthem):
Measles Maculopapular Rash with Koplik spots:
Definition
1. EPIDEMIOLOGY
Global Disease Burden
- Endemic in virtually all parts of the world
- In 1980, before widespread vaccine use: ~2.6 million measles deaths per year
- By 2018: ~9.7 million cases and >140,000 measles-related deaths globally (73% reduction in deaths since 2000)
- Accounts for ~2% of under-five mortality worldwide
- Epidemics occur when susceptible children reach ~40% of population
- In virgin communities: >90% of the community infected when disease is introduced
- Pre-immunization programme: cyclical peaks every 3 years; ~2.47 lakh cases in 1987
- Post-UIP (2018): 20,895 cases and 34 deaths
- States most affected (2018): West Bengal, Assam, J&K, Maharashtra, Delhi, UP, Rajasthan
Epidemiological Determinants
A. Agent Factors
| Factor | Details |
|---|---|
| Agent | RNA Paramyxovirus; only one serotype |
| Reservoir | Humans only; no animal reservoir |
| Survival | Cannot survive outside human body for long; retains infectivity at sub-zero temperatures |
| Source | Only a case of measles; no carriers known |
| Infective material | Secretions of nose, throat, respiratory tract (prodromal + early rash stage) |
| Communicability | ~4 days before to 4 days after rash appearance; highly infectious during prodrome |
| Second attack | Rare; one serotype only; infection gives lifelong immunity |
B. Host Factors
| Factor | Details |
|---|---|
| Age | 6 months - 3 years (developing countries); >5 years (developed countries); post-vaccine era: older age groups affected |
| Sex | Equal incidence in males and females |
| Immunity | One attack gives lifelong immunity; maternal antibody protects infants up to 6-9 months |
| Nutrition | Measles hits malnourished children harder; precipitates kwashiorkor in borderline cases |
| Susceptibility | Universal in absence of immunity |
C. Environmental Factors
- Seasonal trend: Temperate zones - peaks in late winter/spring; tropics - during dry cooler months
- Overcrowding promotes spread
- Epidemic cycle: Every 2-3 years (pre-vaccine); longer cycles with higher vaccination coverage
- Virus spreads efficiently in conditions of poor ventilation and crowding
D. Transmission
- Airborne (primary route) - droplets and droplet nuclei
- Direct contact with nasal/throat secretions
- Indirect contact - freshly soiled articles with nasopharyngeal secretions
Incubation Period
- 10-14 days (range 7-18 days; typically about 10 days to fever, ~14 days to rash)
2. CLINICAL FEATURES
Prodromal Stage (3-5 days)
- High fever, severe malaise
- The 3 C's: Coryza, Cough, Conjunctivitis
- Koplik spots (pathognomonic): bluish-white/grayish spots on erythematous buccal mucosa, opposite lower molars; appear 1-2 days before rash
Eruptive Stage
- Maculopapular rash: starts on face and behind ears → spreads downward (centrifugal, cephalocaudal)
- Rash lasts ~5-6 days; may coalesce
- Fever rises with rash, subsides as rash fades
- Rash fades in order of appearance, leaving brownish discoloration
Complications
- Otitis media (most common complication)
- Pneumonia (most common cause of death)
- Laryngotracheobronchitis (Croup)
- Encephalitis (1 in 1000 cases)
- Subacute Sclerosing Panencephalitis (SSPE) - rare, fatal; years later
- Malnutrition/Kwashiorkor in developing countries
- Blindness (vitamin A deficiency + corneal ulceration)
3. PREVENTION
A. Active Immunization (Primary Prevention)
- Live attenuated measles vaccine (Oka/Edmonston-Zagreb strain)
- Schedule: 2-dose strategy (MCV1 + MCV2) - see SAQ above for full details
- Target: ≥95% coverage nationally; ≥80% in every district
- Achieves 95-98% protection (1 or 2 doses)
- Global target (WHO/UNICEF): reduce measles mortality by ≥95% vs. year 2000 levels
B. Passive Immunization
- Immunoglobulin (human): 0.25 ml/kg IM within 3-4 days of exposure
- For high-risk susceptible contacts (malnourished children, immunocompromised)
C. Vitamin A Supplementation
- WHO recommends vitamin A to all children with measles to reduce complications and mortality
- Dose: 200,000 IU orally for 2 days (children >12 months); 100,000 IU (<12 months)
- Reduces measles-related blindness and pneumonia mortality
D. Supplementary Immunization Activities (SIAs)
- Mass vaccination campaigns targeting unvaccinated/under-vaccinated children
- Conducted in areas with low routine coverage or during outbreaks
4. CONTROL MEASURES
A. Case Management
| Measure | Details |
|---|---|
| Notification | Notifiable disease - report promptly |
| Isolation | Isolate for 7 days from onset of rash (more than covers communicability period) |
| Treatment | Symptomatic; vitamin A; antibiotics for secondary bacterial complications |
| Hospitalize | Severe cases - pneumonia, encephalitis, malnutrition |
B. Contact Management
- Identify and vaccinate susceptible contacts within 3 days of exposure (post-exposure vaccination)
- High-risk susceptibles (infants <9 months, immunocompromised): administer immunoglobulin within 3-4 days
- Exclude unvaccinated susceptible children from school for 21 days from last exposure
C. Environmental Measures
- Improve ventilation in schools, hostels, hospitals
- Promote hand hygiene and respiratory etiquette
- Airborne + contact precautions in healthcare settings
D. Surveillance
- Case-based measles-rubella surveillance with adequate laboratory support (IgM serology, RT-PCR)
- Maintain vaccination records and track outbreaks
- Investigation and containment of clusters
5. ERADICATION
- Humans are the only reservoir
- No known carrier state
- Only one serotype
- An effective, safe, affordable vaccine exists
- Only 2 doses needed; more heat-stable vaccine developed
- Immunization coverage of ≥96% of children under 1 year
- Prevention of accumulation of immunity gaps across generations
Summary Table
| Parameter | Details |
|---|---|
| Causative agent | RNA Paramyxovirus (1 serotype) |
| Reservoir | Humans only; no carriers |
| Transmission | Airborne (droplets/nuclei), contact |
| Incubation | 10-14 days |
| Communicability | 4 days before to 4 days after rash |
| SAR | ~100% in susceptibles |
| Pathognomonic sign | Koplik spots |
| Vaccine | Live attenuated, 2-dose (MCV1 + MCV2) |
| Isolation | 7 days from rash onset |
| Immunity | Lifelong after natural infection |
Drug resistance tb in story format in simple language
drug resistant tuberculosis MDR TB chest xray
This diagnostic image is a posterior-anterior (PA) chest radiograph illustrating pulmonary manifestations of multi-drug resistant tuberculosis (MDR-TB). The radiograph reveals significant pathology characterized by bilateral, asymmetric opacities and infiltrates, predominantly involving the upper and mid-lung zones. Specifically, there are dense, patchy alveolar and interstitial infiltrates visible in both apical regions. Within these areas of consolidation, several lucent, thin-walled cavitary lesions are present, which are classic radiographic hallmarks of post-primary or secondary tuberculosis reactivation. The mediastinal shadow appears within normal limits, and there is no evidence of significant pleural effusion. The visible skeletal structures show no acute fractures, though the clinical context notes an underlying diagnosis of systemic lupus erythematosus (SLE), which may contribute to the patient's immunosuppression. This image serves as an educational example of advanced pulmonary infectious disease and the radiographic appearance of cavitation in the setting of drug-resistant mycobacterial infection.
A comparison chart demonstrating a live image analysis interface for tuberculosis (TB) drug resistance diagnosis from chest X-rays (CXR). The graphic is divided into four chronological columns: 0.00 seconds, 5.00 seconds, 10.00 seconds, and shutter pressing time at 15 seconds. Each column displays a cropped diagnostic image focusing on the bilateral mid-to-lower lung fields and mediastinal borders. Below each image are AI-generated probability bars for five clinical classifications: Pre-XDR (pre-extensively drug-resistant TB), DR-TB (drug-resistant TB), DS-TB (drug-susceptible TB), XDR-TB (extensively drug-resistant TB), and MDR-TB (multidrug-resistant TB). The visual illustrates the real-time evolution of the deep learning model's diagnostic confidence. For instance, at 5.00 seconds, XDR-TB shows a 100% probability, while at the final shutter time (15 seconds), DS-TB becomes the most likely prediction at 66%. This infographic highlights the application of 'fast image analysis' in clinical informatics and infectious disease screening.
🫁 The Story of the Stubborn Bug
Drug-Resistant Tuberculosis - Told as a Story
Chapter 1: The Villain Arrives
Chapter 2: The Mutation Game
Chapter 3: The Big Mistake - Incomplete Treatment
Chapter 4: The Names of the Monster
| Name | What it means | In plain language |
|---|---|---|
| Mono-resistant TB | Resistant to ONE drug | The bug dodges one punch |
| Poly-resistant TB | Resistant to MORE than one drug (but not both Isoniazid + Rifampicin) | The bug is getting tougher |
| MDR-TB (Multi-Drug Resistant) | Resistant to at least Isoniazid AND Rifampicin - the two most powerful first-line drugs | The main weapons don't work anymore |
| Pre-XDR-TB | MDR-TB + resistant to a fluoroquinolone OR a second-line injectable | Almost impossible to treat |
| XDR-TB (Extensively Drug Resistant) | MDR-TB + resistant to a fluoroquinolone AND a second-line injectable (amikacin/streptomycin) | One of the hardest infections to treat |
Chapter 5: How Did We Get Here? - The Three Villains
Villain 1 - The Careless Patient 🧍
- Stopping medicines early ("I feel better")
- Skipping doses
- Not knowing why full treatment matters
- Poverty and social barriers making it hard to access medicines
Villain 2 - The Failing System 🏥
- Doctors prescribing the wrong drug combination or wrong dose
- No guidelines, or guidelines not followed
- Poor supervision and monitoring of patients
- Lack of trained health workers
Villain 3 - The Bad Medicine 💊
- Drug stockouts (medicines running out mid-treatment)
- Poor quality medicines
- Wrong storage (drugs damaged by heat or sunlight)
- Wrong dosage combinations in the packet
Chapter 6: The Battle Gets Harder - Treating MDR-TB
- Treatment duration: At least 18-24 months (compared to 6 months for normal TB)
- Number of drugs: 5 drugs in the intense phase, then 4 drugs in the continuation phase
- Medicines used: Bedaquiline, Linezolid, Moxifloxacin, Clofazimine, Cycloserine - names even doctors struggle to pronounce
- Cost: Second-line drugs cost 30 times more than normal TB drugs
- Side effects: These medicines can damage hearing, cause nerve pain, affect the liver, and disturb mental health
Chapter 7: The Even Scarier Monster - XDR-TB
Chapter 8: India's Story
- Primary MDR-TB in India: ~2.8% of new cases
- MDR-TB in retreatment cases: ~12%
- Though the percentage sounds small, because India has so many TB patients, this translates into very large absolute numbers of people suffering from MDR-TB
Chapter 9: Can We Win? - Prevention and Control
For the Patient
- Take ALL your medicines, EVERY day, for the FULL duration - no skipping, no stopping early
- DOTS (Directly Observed Treatment, Short-course) - a health worker watches you swallow your pill every day to make sure you don't miss a dose
- Inform your doctor immediately if you feel side effects rather than stopping on your own
For the Healthcare System
- Proper diagnosis with drug susceptibility testing before starting treatment
- Correct drug regimens, correct doses
- Regular monitoring of patient progress
- Adequate drug supply - no stockouts
- Rapid molecular tests (like GeneXpert/CB-NAAT) that detect resistance within hours, not weeks
For Society
- Improve ventilation and reduce overcrowding
- Address poverty and malnutrition that make people more vulnerable
- TB awareness campaigns
- Contact tracing - finding people who were exposed
Epilogue: What Raju Learned
"Six months of pills felt like too much. Two years of second-line treatment felt like forever. Please - finish your medicines the first time."
The Bottom Line in One Line:
Malaria
What format would you like for Malaria? · Which aspects should be covered?
malaria Plasmodium life cycle blood smear parasite
A pathophysiology diagram illustrating the complex life cycle of the Plasmodium parasite, responsible for malaria, between a female Anopheles mosquito and a human host. The cycle is divided into two primary environments. Within the human host, the parasite undergoes liver stages, where sporozoites infect hepatocytes and multiply into merozoites. This is followed by the blood stages, an asexual intraerythrocytic cycle where merozoites infect red blood cells (RBCs) and progress through ring, trophozoite, and schizont stages before rupturing to infect new RBCs. Sexual differentiation occurs when some merozoites develop into male and female gametocytes. The mosquito stages begin when a mosquito ingests these gametocytes during a blood meal. Within the mosquito's midgut and salivary glands, the parasite undergoes sexual reproduction and development, progressing from gametes to zygote, ookinete, and oocyst. The mature oocyst releases sporozoites that migrate to the mosquito's salivary glands for transmission back to a human host, completing the cycle. This educational diagram is essential for understanding parasitology, infectious disease transmission, and the biological targets for malaria treatment and prevention.
An educational pathophysiology diagram illustrating the initial stages of the Plasmodium parasite life cycle within a human host. The central element is a brown-outlined human silhouette. On the figure's right shoulder, a disproportionately large, detailed female Anopheles mosquito is depicted in the act of taking a blood meal, symbolizing the inoculation of sporozoites. Four vertically aligned red circular icons are positioned in the central chest area, representing the hematogenous spread of parasites following the mosquito bite. Below these, a stylized brown illustration of the liver is placed in the upper abdominal region, signifying the exoerythrocytic stage where sporozoites invade hepatocytes to proliferate as schizonts or persist as hypnozoites (specifically in P. vivax and P. ovale). The diagram serves as a visual summary of the vector-to-host transmission and the subsequent hepatic involvement in malaria infection.
A two-part pathophysiology diagram illustrating the Plasmodium falciparum life cycle stages in human blood and the molecular mechanism of cytoadherence. Section A, 'Merozoite invasion and replication in red blood cells,' depicts blue oval-shaped merozoites invading a red blood cell (RBC). An arrow leads to an infected red blood cell (pRBC) expressing the PfEMP1 protein on its surface, represented as segmented bead-like structures. Section B, 'Cytoadherence & sequestration,' provides a molecular schematic of the PfEMP1 protein's domain structure, including DBL1̑ (black), CIDR1̑ (green), DBL2̑ (red), and CIDR1̑ (black), followed by a transmembrane (TM) domain. Dotted arrows indicate specific binding interactions between these protein domains and host receptors on the vascular endothelium. Specifically, the CIDR1̑ domain is shown interacting with IgM (green star-shaped icon) and CD36 (green clover-shaped receptor), while the DBL2̑ domain interacts with CD31/PECAM-1 (red pentagonal receptor) on the endothelial surface. This diagram summarizes the molecular basis of malaria parasite sequestration in the human microvasculature.
A medical educational diagram illustrating the Intra-erythrocytic Development Cycle (IDC) of the malaria parasite (Plasmodium spp.). The flowchart depicts two divergent pathways within a host red blood cell (RBC). The primary loop shows the asexual replication cycle, where parasites (teal circles) undergo maturation from a single parasite body into schizonts with multiple internal bodies, eventually bursting to release merozoites for further RBC infection. A secondary pathway illustrates sexual commitment, marked by the expression of the transcription factor AP2-G (represented by purple circles). Following this commitment, the parasites differentiate into sexual stages called gametocytes (yellow circles). The final stage of this differentiation demonstrates the formation of distinct male and female gametocytes, identified by gender symbols. The diagram highlights the biological decision-making process between continued asexual multiplication for within-host survival and the production of gametocytes for transmission to the mosquito vector, a key concept in malaria pathophysiology and lifecycle research.
malaria epidemiology treatment prevention
MALARIA - Complete Exam Notes (SAQ + LAQ)
PART A: SAQs
SAQ 1: Species of Plasmodium
| Species | Distribution | Periodicity | Special Features |
|---|---|---|---|
| P. vivax | Widest worldwide | Benign tertian (48 hrs) | Hypnozoites → relapses; Duffy antigen required for entry |
| P. falciparum | Tropics/subtropics | Malignant tertian (36-48 hrs) | Most dangerous; cytoadherence; cerebral malaria |
| P. malariae | Restricted | Quartan (72 hrs) | Nephrotic syndrome; recrudescence (not relapse) |
| P. ovale | Tropical Africa mainly | Benign tertian (48 hrs) | Hypnozoites → relapses; rare in India |
SAQ 2: Life Cycle of Plasmodium
A. Human Cycle (Asexual)
- Sporozoites injected → enter liver hepatocytes
- Multiply → form hepatic schizonts → rupture → release merozoites into blood
- P. vivax & P. ovale: some become hypnozoites (dormant in liver → cause relapses)
- Duration: 5.5-15 days depending on species
- Merozoites invade RBCs → form ring trophozoite → mature trophozoite → erythrocytic schizont → rupture → release merozoites (causing fever)
- Cycle repeats every 48 hrs (vivax/falciparum) or 72 hrs (malariae)
- Some merozoites → gametocytes (male = microgametocyte; female = macrogametocyte)
B. Mosquito Cycle (Sexual)
- Female Anopheles ingests gametocytes during blood meal
- In mosquito gut: microgametes + macrogamete → zygote → ookinete → oocyst
- Oocyst ruptures → releases sporozoites → migrate to salivary glands
- Mosquito now infective; injects sporozoites into next human host
- Extrinsic incubation period: 10-12 days (must survive at least this long to transmit)
SAQ 3: Malaria Vectors in India
| Vector | Area | Special Notes |
|---|---|---|
| An. culicifacies | Rural & peri-urban, peninsular India | Most important rural vector; zoophilic; species A = vector for both Pf & Pv |
| An. stephensi | Urban & industrial areas | Main urban vector; breeds in overhead tanks, cisterns |
| An. fluviatilis | Hills/forests | Breeds in moving water; highly anthropophilic; efficient vector |
| An. minimus | North-east India, hills | Forest-fringe areas |
| An. sundaicus | Coastal areas | Breeds in brackish water |
| An. philippinensis | North-east, West Bengal | Paddy field breeding |
- Density - must be above "critical density" for transmission
- Life span - must survive ≥10-12 days after infective meal (extrinsic incubation period)
- Anthropophily - preference for human blood
- Endophily - indoor resting habits (basis for IRS strategy)
- Vectorial capacity - combined effect of all factors
SAQ 4: Malariometric Indices
Pre-Eradication Era (Clinical measures)
| Index | Definition |
|---|---|
| Spleen Rate | % of children (2-10 years) with enlarged spleen; measures endemicity |
| Average Enlarged Spleen (AES) | Average size of enlarged spleen; refinement of spleen rate |
| Parasite Rate | % of children (2-10 years) with malaria parasites in blood film |
| Infant Parasite Rate | % of infants <1 year with parasites; most sensitive index of recent transmission; zero for 3 consecutive years = no transmission |
| Parasite Density Index | Average degree of parasitaemia among positive slides |
| Proportional Case Rate | Cases diagnosed as malaria per 100 OPD attendees |
Eradication Era (Parasitological measures)
| Index | Definition |
|---|---|
| API (Annual Parasite Incidence) | Confirmed malaria cases per 1000 population per year |
| ABER (Annual Blood Examination Rate) | Blood slides examined per 100 population per year; target ≥10% |
| SPR (Slide Positivity Rate) | % of slides positive among total slides examined |
| SFR (Slide Falciparum Rate) | % of falciparum slides among total slides examined |
SAQ 5: Treatment of Malaria (India Guidelines 2013)
P. vivax (Uncomplicated)
- Chloroquine 25 mg/kg over 3 days (Day 1: 10 mg/kg; Day 2: 10 mg/kg; Day 3: 5 mg/kg)
- Primaquine 0.25 mg/kg/day × 14 days (to prevent relapses from hypnozoites)
- Relapse rate in India: ~30%
- Contraindications to Primaquine: G6PD deficiency, infants, pregnant women
P. falciparum (Uncomplicated)
- ACT: Artesunate (3 days) + Sulphadoxine-Pyrimethamine (1 day)
- + Single dose Primaquine 0.75 mg/kg on Day 2 (to clear gametocytes)
- North-East states (SP resistance): Artemether + Lumefantrine (co-formulated)
- Artemisinin monotherapy banned in India (prevents resistance)
Malaria in Pregnancy
| Trimester | P. falciparum | P. vivax |
|---|---|---|
| 1st trimester | Quinine | Chloroquine |
| 2nd & 3rd trimester | ACT | Chloroquine |
| All trimesters | Primaquine contraindicated | - |
Mixed Infections (Pf + Pv)
- Treat as P. falciparum
Drug Resistance
- Suspect if no response within 72 hours of full ACT
- Treat with Quinine + Tetracycline/Doxycycline
- Report to District/State Malaria Officer
PART B: LAQ - Malaria (Epidemiology, Prevention & Control)
Definition
1. GLOBAL DISEASE BURDEN
- 229 million malaria cases in 2019 across 87 endemic countries
- Sub-Saharan Africa bears the greatest burden
- Before eradication era: hundreds of millions infected; tens of millions dead
- Malaria case incidence reduced from 80 → 57 per 1000 population at risk (2000-2019)
- India: Largest absolute reduction in SE Asia - ~20 million cases (2000) → 5.6 million (2019) → 0.34 million (2019)
- Deaths in India: 73 in 2019; 91% of cases from 10 high-burden states (Odisha, Chhattisgarh, Jharkhand, MP, NE states, Gujarat, Rajasthan, WB, Karnataka, Maharashtra)
2. EPIDEMIOLOGICAL DETERMINANTS
A. Agent Factors
- P. vivax / P. ovale: 12-17 days
- P. falciparum: 7-14 days (shortest; most dangerous)
- P. malariae: 18-40 days
B. Host Factors
| Factor | Details |
|---|---|
| Age | All age groups at risk in India (unstable transmission → low herd immunity); children more affected in intense transmission foci |
| Sex | Males more exposed (outdoor work, forest areas) |
| Immunity | Partial immunity develops in hyperendemic areas; wanes when transmission falls; sickle cell trait gives relative protection against P. falciparum |
| Pregnancy | High risk - severe anaemia, low birth weight, maternal mortality |
| G6PD deficiency | Risk of haemolysis with primaquine |
| Nutrition | Malnutrition increases severity |
C. Environmental Factors
- Season: Peak transmission during and after monsoon (June-November); lag of 6-8 weeks after floods
- Ecology: Forest/forest-fringe areas have highest burden; tribal populations most affected
- Urbanization: An. stephensi thrives in urban water storage → urban malaria
- Irrigation projects: Create new breeding sites → epidemics
- Temperature: 20-30°C optimal; affects mosquito breeding and parasite development
- India = unstable malaria transmission - most population has low immunity → all age groups at risk
D. Transmission Routes
- Vector (primary): Bite of infected female Anopheles (dusk-to-dawn feeding)
- Blood transfusion: Transfusion malaria (all 4 species; no exo-erythrocytic stage; no relapses)
- Congenital: Mother to fetus via placenta
- Needle-sharing: IV drug users
3. CLINICAL FEATURES
Classic Malarial Paroxysm (3 Stages)
| Stage | Duration | Features |
|---|---|---|
| Cold stage | 15-60 min | Intense chills, shivering, teeth chattering; temperature rising |
| Hot stage | 2-6 hours | High fever (40-41°C), hot and dry skin, headache, vomiting |
| Sweating stage | 2-4 hours | Profuse sweating, temperature falls, patient feels exhausted but better |
- Every 48 hours (tertian): P. vivax, P. falciparum, P. ovale
- Every 72 hours (quartan): P. malariae
Complications (Mainly P. falciparum - "Malignant Malaria")
| Complication | Features |
|---|---|
| Cerebral malaria | Altered consciousness, seizures, coma; most dangerous |
| Severe anaemia | Haemolysis + dyserythropoiesis |
| Acute pulmonary oedema / ARDS | |
| Hypoglycaemia | Especially with quinine treatment |
| Acute renal failure (ARF) | "Blackwater fever" in falciparum |
| Blackwater fever | Massive haemolysis → haemoglobinuria → dark urine |
| Algid malaria | Septic shock picture |
| Thrombocytopenia | |
| Nephrotic syndrome | P. malariae (quartan malaria nephropathy) |
| Splenic rupture | P. vivax |
4. DIAGNOSIS
| Method | Details |
|---|---|
| Peripheral blood smear (Gold standard) | Thick smear (detection) + Thin smear (species identification); Giemsa stain |
| RDT (Rapid Diagnostic Test) | HRP-2 antigen (Pf specific) + pLDH (pan-species); result in 15-20 min |
| QBC (Quantitative Buffy Coat) | Fluorescent microscopy; sensitive but expensive |
| PCR | Most sensitive; not for routine field use |
| Serology | Not for acute diagnosis; epidemiological studies |
5. PREVENTION & CONTROL
A. Case Management (Surveillance + Treatment)
- Passive case detection: Fever cases attending health facilities
- Active case detection: Field workers screening door-to-door in high-risk areas
- Early diagnosis + complete treatment = interrupts transmission + prevents deaths
- No scope for presumptive treatment under India's 2013 policy - all cases must be confirmed
B. Vector Control (Integrated Vector Management - IVM)
1. Anti-Adult Measures
- Indoor Residual Spraying (IRS): Insecticide sprayed on interior walls; kills resting endophilic mosquitoes; DDT (still used in India where permitted), Synthetic pyrethroids, Malathion
- Insecticide Treated Nets (ITNs) / Long-Lasting Insecticidal Nets (LLINs): Physical barrier + insecticide kill; most cost-effective intervention
- Personal protection: Repellents (DEET), protective clothing, mosquito coils/mats
2. Anti-Larval Measures (Source Reduction)
- Environmental management: Eliminate breeding sites - drainage, filling stagnant water
- Biological control: Larvivorous fish (Gambusia affinis, Lebistes reticulatus) introduced into water bodies
- Temephos (Abate): Larvicide safe for drinking water sources
- Bacillus thuringiensis israelensis (Bti): Biological larvicide
3. Key principle: Shorten mosquito lifespan to <10 days (below extrinsic incubation period) → transmission impossible
C. Chemoprophylaxis
| Drug | Indication |
|---|---|
| Chloroquine 300 mg weekly | P. vivax endemic areas; travellers |
| Doxycycline 100 mg daily | P. falciparum endemic areas; chloroquine-resistant areas |
| Mefloquine | High-risk travellers |
| Atovaquone-Proguanil | Short-term travellers |
D. Malaria Vaccine
- RTS,S/AS01 (Mosquirix): First approved malaria vaccine (WHO, 2021)
- Targets P. falciparum circumsporozoite protein (pre-erythrocytic)
- Efficacy: ~36-56% against clinical malaria in children
- 4-dose schedule (0, 1, 2, 20 months)
- Recommended for children in sub-Saharan Africa and other moderate-to-high Pf endemic areas
- R21/Matrix-M: Newer vaccine (2023 WHO approval); higher efficacy (~75-80%)
6. NATIONAL MALARIA CONTROL PROGRAMME (NMCP) / NVBDCP
- Surveillance and case management (passive + active detection, early treatment)
- Integrated vector management (IRS, LLINs, anti-larval)
- Epidemic preparedness and early response
- Supportive interventions (BCC, intersectoral collaboration, monitoring)
7. KEY DEFINITIONS (WHO)
| Term | Definition |
|---|---|
| Malaria control | Reducing burden to levels no longer a public health problem |
| Malaria elimination | Interruption of local mosquito-borne transmission; zero incidence in a defined area; surveillance must continue |
| Certification of elimination | WHO certifies after zero local transmission for ≥3 consecutive years |
| Malaria eradication | Permanent worldwide reduction to zero; no further interventions needed |
Summary Table
| Feature | P. vivax | P. falciparum | P. malariae | P. ovale |
|---|---|---|---|---|
| Periodicity | 48 hrs (Benign Tertian) | 36-48 hrs (Malignant Tertian) | 72 hrs (Quartan) | 48 hrs (Benign Tertian) |
| Hypnozoites | Yes (relapses) | No (recrudescence) | No (recrudescence) | Yes (relapses) |
| Dangerous complications | Splenic rupture | Cerebral, ARF, ARDS, Blackwater | Nephrotic syndrome | Rare |
| Incubation | 12-17 days | 7-14 days | 18-40 days | 16-18 days |
| Treatment | Chloroquine + Primaquine 14 days | ACT + Primaquine single dose | Chloroquine | Chloroquine + Primaquine |
Tell me the chemoprophylaxis of malaria when to start in story format or easy chart
🦟 Malaria Chemoprophylaxis
When to Start, What to Take, When to Stop
🎬 The Story: Priya is Travelling to a Malaria Zone
🛡️ The Golden Rule
Start BEFORE → Continue DURING → Stop AFTER
- Some drugs need time to build up to protective blood levels before you arrive
- All drugs must continue 4 weeks after leaving the malaria area, because malaria parasites can still be hiding in the liver and emerge later
📊 THE MASTER CHART
Drug-by-Drug: When to Start, Dose, When to Stop
| Drug | Frequency | START (before travel) | DURING stay | STOP (after leaving) | Key Notes |
|---|---|---|---|---|---|
| Chloroquine | Weekly | 1 week before | Every week, same day | 4 weeks after | Low-risk / P. vivax areas |
| Mefloquine | Weekly | 2-3 weeks before ⭐ | Every week, same day | 4 weeks after | High-risk areas; start early to detect side effects |
| Doxycycline | Daily | 1 day before | Every day | 4 weeks after | Chloroquine-resistant Pf areas |
| Proguanil | Daily | 1 day before | Every day | 4 weeks after | Usually combined with chloroquine |
| Atovaquone-Proguanil | Daily | 1-2 days before | Every day | 7 days after ⭐ (shorter!) | Travellers; expensive |
⭐ Mefloquine is the odd one out - start 2-3 weeks early, not just 1 week. This is because it takes time to reach therapeutic levels AND to detect any neuropsychiatric side effects before you're already in a remote jungle.
⭐ Atovaquone-Proguanil can stop just 7 days after leaving (not 4 weeks) because it acts on both liver and blood stages.
🕐 VISUAL TIMELINE (Priya's Trip)
DELHI ODISHA (endemic area) DELHI
| | |
[START]──────────────────[ARRIVE]──────────────[LEAVE]────[STOP]
↑ ↑
Chloroquine: 1 week before ──────────────────────── 4 weeks after
Mefloquine: 2-3 weeks before ─────────────────────── 4 weeks after
Doxycycline: 1 day before ─────────────────────────── 4 weeks after
Atovaquone-P: 1-2 days before ──────────────────────── 7 days after
💊 ADULT DOSES (Park's Table 2)
| Drug | Dose | Tablet Strength |
|---|---|---|
| Chloroquine | 300 mg base once weekly | 2 tabs of 150 mg OR 3 tabs of 100 mg |
| Proguanil | 200 mg once daily | 2 tabs of 100 mg |
| Mefloquine | 250 mg once weekly | 1 tab of 250 mg |
| Doxycycline | 100 mg once daily | 1 capsule of 100 mg |
👥 WHO NEEDS CHEMOPROPHYLAXIS?
✅ Travellers from NON-endemic areas visiting endemic zones
✅ Soldiers posted to malaria-endemic areas (short-term)
✅ Police & labourers working in endemic forests
✅ Pregnant women in high-transmission areas (special rules apply)
✅ Children travelling to endemic areas (dose by BODY WEIGHT)
⚠️ SPECIAL SITUATIONS
Pregnancy 🤰
- Choice of safe drugs is very narrow
- Chloroquine is the safest option for P. vivax areas
- Chemoprophylaxis should ideally be part of antenatal care
- In some cases, prompt treatment of clinical episodes may be preferred over prophylaxis (national policy guides this)
Long-term use (>6 weeks) ⏳
- Chloroquine >5 years at 300 mg/week → screen twice yearly for retinal changes (retinal toxicity)
- If daily 100 mg chloroquine → start eye screening after 3 years
- Mefloquine - does NOT accumulate; safe for long-term if tolerated short-term
- Doxycycline long-term - limited data
Mefloquine Contraindications 🚫
- History of convulsions
- Neuropsychiatric problems
- Cardiac conditions
🧠 The Memory Trick
| Phase | Analogy | Drug rule |
|---|---|---|
| Packing your bags (before trip) | Put armor on EARLY | Start drug 1 day / 1 week / 2-3 weeks before |
| Holiday in malaria zone | Keep armor on EVERY DAY | Take drug without fail throughout stay |
| Back home (after trip) | Armor off only when parasites in liver are dead | Continue 4 weeks after (7 days for Atovaquone-P) |
🔑 One-Line Summary per Drug
| Drug | Remember it as |
|---|---|
| Chloroquine | "1 week early, weekly pill, 4 weeks tail" |
| Mefloquine | "Start 2-3 weeks early to test tolerance, weekly, 4 weeks tail" |
| Doxycycline | "Day before departure, daily dose, 4 weeks tail" |
| Atovaquone-Proguanil | "Day before, daily, only 7-day tail" (acts on liver stage too!) |
⚠️ Important note from Park's: Chemoprophylaxis has become unreliable due to drug resistance. It should always be combined with personal protection (insecticide-treated nets, repellents) and vector control. Neither chemotherapy nor chemoprophylaxis alone can reduce malaria prevalence - proper anti-mosquito measures remain essential.
1. Investigation of Food Poisoning* (Pg. 262) LAQ 1. Food Poisoning - define, causative organisms, Food Poisoning episode in a College Hostel - investigate
food poisoning investigation outbreak epidemiology
<table><thead><tr><th>Name</th><th>Organizational affiliation, address</th><th>Gender</th><th>Expertise</th></tr></thead><tbody><tr><th colspan="4">WHO African region</th></tr><tr><td>Professor Angela Mathee</td><td>Director, Environment and Health Research Unit,<br>South African Medical Research Council<br>Johannesburg, South Africa</td><td>F</td><td>Public health;<br>environmental epidemiology;<br>lead poisoning in African children</td></tr><tr><td>Professor Orish E Orisakwe</td><td>Toxicology Unit, Faculty of Pharmacy,<br>University of Port Harcourt Port Harcourt, Nigeria<br><br>On roster of toxicological and epidemiological experts for Joint FAO/WHO Expert Committee on Food Additives (JECFA), 2011–2015</td><td>M</td><td>Environmental toxicology;<br>analytical toxicology</td></tr><tr><th colspan="4">WHO Region of the Americas</th></tr><tr><td>Professor David Bellinger</td><td>Harvard Medical School Children's Hospital, Boston (MA), USA<br><br>Chair of the guideline development group<br><br>On roster of toxicological and epidemiological experts for Joint FAO/WHO Expert Committee on Food Additives (JECFA), 2011–2015</td><td>M</td><td>Neurotoxic effects of lead; epidemiology;<br>environmental health</td></tr><tr><td>Dr Mary Jean Brown</td><td>Previously: Lead Poisoning Prevention Branch (until August 2016),<br>Centers for Disease Control and Prevention (CDC), Atlanta (GA), USA<br><br>Now: Adjunct Assistant Professor, Harvard Chan School of Public Health Boston (MA), USA</td><td>F</td><td>Effects of lead on children's health;<br>prevention and management of lead exposure</td></tr><tr><td>Professor Amalia Laborde</td><td>Director<br><br>Department of Toxicology, Centre for Toxicological Information and Advice, Faculty of Medicine, Clinical Hospital, Montevideo, Uruguay<br><br>Director of WHO Collaborating Centre for Human Environmental Toxicology; member of WHO children's environmental health network</td><td>F</td><td>Clinical and occupational toxicology;<br>occupational and environmental exposure to lead;<br>prevention of poisoning</td></tr><tr><td>Professor Philip J Landrigan</td><td>Previously: Icahn School of Medicine at Mount Sinai,<br>New York City (NY), USA<br><br>Now: Schiller Institute for Integrated Science and Society,<br>Boston College, Boston (MA), USA<br><br>Director of WHO Collaborating Centre for Children's Environmental Health</td><td>M</td><td>Children's environmental health;<br>prevention of lead exposure</td></tr></tbody></table>
This infographic presents a computational epidemiology framework for measles outbreak risk assessment. The diagram is organized into four interconnected panels: (1) Activity-based population network G(V, E) which models contacts between individuals using demographic data from the US Census and National Immunization Surveys; (2) Underimmunized spatial significant clusters, depicted as a zip code-level network. Here, zip codes are nodes (light green squares) connected by shared geographical boundaries, containing clusters of vaccinated (green points) and unvaccinated (yellow points) individuals identified via network-based scan statistics; (3) Criticality analysis, utilizing a network epidemic model and agent-based simulation to visualize infection progression through susceptible (yellow nodes), infected (red nodes), and recovered (light blue nodes) states; and (4) Network properties of the unvaccinated sub-network (Gu), focusing on eigenvector centrality and degree analysis to understand the probability of large outbreaks. The workflow demonstrates how local immunization gaps translate into systemic risk within a synthetic social contact network.
SAQ: Investigation of Food Poisoning (Park's p. 262 / Block p. 282)
Investigation of an Outbreak of Food Poisoning
Step 1: Secure a Complete List of All Persons Involved
- Interview all persons who shared the suspected food (including those who did NOT fall ill - they are the controls)
- Administer questionnaires covering:
- Foods eaten in the previous 48 hours and place of consumption
- Time of onset of symptoms
- Symptoms in order of occurrence: nausea, vomiting, diarrhoea, abdominal pain, headache, fever, prostration
- Personal data: age, sex, residence, occupation
- Questionnaires also administered to kitchen employees and food handlers
Step 2: Laboratory Investigations
| Specimen | From Whom | Purpose |
|---|---|---|
| Stool samples | Affected persons + food handlers | Isolate causative organism |
| Vomit samples | Affected persons | Identify toxin/organism |
| Remnants of suspected food | Kitchen/hostel store | Culture + toxin detection |
| Blood | Affected persons | Antibody titres (retrospective diagnosis) |
- Specimens inoculated into appropriate culture media
- Examine aerobically AND anaerobically (for Clostridium)
- Determine total bacterial count + relative numbers of each organism
- Phage typing of organisms to complete the investigation
- Animal experiments if needed (e.g., feed rhesus monkeys with food remnants; protection tests with mice for botulism)
Step 3: Environmental Study
- Inspect eating places, kitchen(s), storage areas
- Question food handlers about:
- Food preparation methods and temperatures
- Storage conditions (refrigeration? duration?)
- Hygiene practices
- Any sick persons handling food
- Look for evidence of contamination - rodent droppings, improper cooking, cross-contamination
Step 4: Data Analysis
- Analyze data by descriptive epidemiology - Time, Place, Person distribution
- Calculate Food-Specific Attack Rates:
- Compare attack rates in those who ate vs. did not eat each food item
- The food with the highest attack rate among those who ate it AND lowest rate among those who did not eat it = suspect vehicle
- Undertake a case-control study to establish epidemiological association between illness and specific food
Step 5: Calculate Incubation Period
- Helps identify the probable causative agent
- Plot an epidemic curve (cases on Y-axis vs. time of onset on X-axis)
- Calculate mean/median incubation period → match to known organisms
Step 6: Control Measures & Reporting
- Remove or destroy the incriminated food
- Treat affected persons
- Instruct food handlers on hygiene
- Notify health authorities (food poisoning is a notifiable condition)
- Issue public health advice to prevent further cases
LAQ: Food Poisoning - Definition, Causative Organisms & Investigation of a College Hostel Outbreak
1. DEFINITION
- Living bacteria or their toxins, OR
- Inorganic chemical substances, OR
- Poisons derived from plants and animals
Characteristic Features (Triad):
- History of ingestion of a common food
- Attack of many persons at the same time
- Similarity of signs and symptoms in the majority of cases
2. TYPES & CAUSATIVE ORGANISMS
A. Non-Bacterial Food Poisoning
- Chemical: Arsenic, pesticides, fertilizers, cadmium, mercury, lead
- Plant toxins: Mushroom poisoning (Amanita species), solanine (potatoes)
- Animal toxins: Puffer fish (tetrodotoxin), shellfish
B. Bacterial Food Poisoning
| Organism | Type | Incubation Period | Key Features |
|---|---|---|---|
| Salmonella (S. typhimurium, S. enteritidis) | Infective | 12-24 hours | Fever + diarrhoea; from meat, eggs, poultry; 1% mortality |
| Staphylococcus aureus | Toxic (enterotoxin) | 2-4 hours (shortest) | No fever; violent vomiting; heat-stable toxin; from custards, cream, milk; food handlers with boils/nasal carriers |
| Clostridium botulinum | Toxic (exotoxin) | 18-36 hours | NEUROLOGICAL symptoms - diplopia, dysphagia, ptosis, dysarthria; NO GI symptoms; from home-canned foods; fatal (2/3 die) |
| Clostridium perfringens | Infective + Toxic | 8-24 hours | Diarrhoea + crampy pain; vomiting rare; from reheated meat, stews |
| Bacillus cereus | Toxic | 1-6 hours (emetic) / 8-16 hours (diarrhoeal) | Emetic type: fried rice; Diarrhoeal type: meat, vegetables |
| Vibrio parahaemolyticus | Infective | 12-24 hours | Seafood; explosive diarrhoea |
| E. coli (ETEC, EHEC) | Infective/Toxic | 12-72 hours | Traveller's diarrhoea; O157:H7 → HUS |
Quick Memory Aid for Incubation Periods
Shortest (1-6 hrs) → Staph aureus / B. cereus emetic type
Short (6-12 hrs) → B. cereus diarrhoeal / Cl. perfringens
Medium (12-24 hrs) → Salmonella / Vibrio
Longest (18-36 hrs) → Cl. botulinum
Differential Diagnosis: Food Poisoning vs. Cholera
| Feature | Cholera | Food Poisoning |
|---|---|---|
| Epidemiology | Epidemic; secondary cases | Single group, common meal; NO secondary cases |
| Incubation | Few hours to 5 days | 1-24 hours |
| Onset | With purging | With vomiting |
| Vomiting | Effortless, watery | Single, severe, mucus/blood streaked |
| Stools | Rice-water, inoffensive | Frequent, offensive, mucus/blood |
| Fever | Absent | Up to 100-102°F |
| Tenesmus | None | Yes |
| Dehydration | Very marked | Distinct |
3. LAQ SCENARIO: Food Poisoning in a College Hostel - Investigation
STEP 1: Confirm the Diagnosis (Verify the Outbreak)
- Establish that this is indeed food poisoning (not just a few coincidental cases)
- Define a case: Any hostel student who ate dinner on Monday and developed ≥2 of: nausea, vomiting, diarrhoea, abdominal cramps within 24 hours
- Count cases → Attack Rate = 60/150 = 40% - confirms an outbreak
STEP 2: Identify All Exposed Persons
- Get the complete dining register of who ate that night's dinner
- Make a line list of all affected and unaffected students:
- Name, room number, age, sex
- What they ate at dinner (every dish)
- Time of first symptom
- Symptoms experienced
STEP 3: Clinical Assessment
- Examine affected students; record:
- Severity (mild/moderate/severe)
- Symptom pattern - vomiting prominent? Fever present? Neurological symptoms?
- Duration of illness
- Hospitalize severe cases (dehydration, neurological signs)
- This symptom pattern helps guess the organism before lab results:
| If you see... | Think... |
|---|---|
| Vomiting within 2-4 hrs, no fever | Staph aureus |
| Diarrhoea + fever after 12-24 hrs | Salmonella |
| Diarrhoea, no fever, 8-24 hrs | Cl. perfringens |
| Neurological signs, no GI | Botulism (emergency!) |
| Fried rice eaten, vomiting 1-6 hrs | B. cereus |
STEP 4: Laboratory Investigations
From Patients:
- Stool samples × 3 (for culture and sensitivity, ova & cysts)
- Vomit samples (if available within first few hours)
- Blood for culture (if fever/bacteraemia suspected) and serology (retrospective)
- Rectal swabs if stool sample unavailable
From Food & Kitchen:
- Collect remnants of all dishes served at the suspected meal (rice, dal, meat, salad, desserts, milk/curd)
- Swabs from cooking vessels, serving utensils, chopping boards, refrigerator
- Water sample from hostel water supply
- Culture specimens aerobically AND anaerobically
- Determine total bacterial count and identify organism proportions
- Phage typing if Staph/Salmonella suspected
From Food Handlers:
- Stool culture of all kitchen staff and food handlers
- Examine for boils, skin infections, nasal carriage (Staph)
- Check for any sick kitchen staff on the day of cooking
STEP 5: Environmental Investigation
| Area | What to Look For |
|---|---|
| Storage | Proper refrigeration? Food stored at safe temperature (<5°C or >60°C)? |
| Cooking | Was food cooked to adequate temperature? Reheated? |
| Cross-contamination | Raw meat near cooked food? Separate chopping boards? |
| Hygiene | Handwashing facilities? Food handler hygiene? |
| Pests | Rodent droppings, cockroach infestation |
| Water supply | Any contamination, chlorination failure |
| Waste disposal | Garbage near kitchen? |
STEP 6: Data Analysis
| Food Item | Ate food + got ill | Ate food + stayed well | Attack Rate (%) | Did NOT eat + got ill | Attack Rate (%) |
|---|---|---|---|---|---|
| Rice | 40 | 20 | 67% | 5 | 10% |
| Chicken curry | 55 | 5 | 92% | 2 | 15% |
| Dal | 30 | 40 | 43% | 10 | 20% |
| Salad | 10 | 50 | 17% | 15 | 25% |
- Plot epidemic curve (no. of cases vs. time of onset) → point-source epidemic = single meal outbreak
- Calculate mean incubation period → helps confirm organism
STEP 7: Identify the Source & Mode of Contamination
- Who cooked the chicken? Did they have a skin infection/boil? (Staph)
- Was chicken stored properly before cooking?
- Was it reheated? At what temperature?
- Was there any mixing of raw and cooked chicken (cross-contamination)?
STEP 8: Control Measures
Immediate:
- Treat all affected students - ORS/IV fluids for dehydration; antibiotics only if indicated (Salmonella/severe cases)
- Remove incriminated food (chicken curry) from dining hall
- Isolate any severely ill students
- Send all food handlers for medical examination
Intermediate:
- Close or temporarily suspend kitchen until cleaned and inspected
- Disinfect cooking vessels, utensils, refrigerators
- De-rat/de-pest the kitchen if evidence of infestation
Long-term:
- Educate kitchen staff on safe food handling, storage, and hygiene
- Establish temperature monitoring for food storage and cooking
- Ensure medical fitness certificates for all food handlers
- Regular microbiological surveillance of food samples
- Ensure proper chlorination and water quality in hostel
STEP 9: Notification & Report
- Notify the District Health Officer (food poisoning is notifiable)
- Submit a formal outbreak investigation report covering:
- Number of cases, attack rate
- Incriminated food, probable causative agent
- Source of contamination
- Control measures taken
- Recommendations to prevent recurrence
Summary Flowchart
Outbreak reported
↓
Confirm outbreak → Define case → Count cases → Calculate attack rate
↓
Line list all exposed persons (ate + did not eat)
↓
Clinical assessment → Symptom pattern → Suspect organism
↓
Laboratory investigations (stool, food, food handlers, water)
↓
Environmental inspection of kitchen
↓
Data analysis → Food-specific attack rates → Incriminate food
↓
Epidemic curve + Incubation period → Confirm organism
↓
Control measures (immediate + long-term)
↓
Notify + Submit report